GV and Nextech contributed to a series B round that boosted the affordable pharmaceutical developer's overall funding to $750m.
US-based affordable medicine developer EQRx secured $500m yesterday in a series B round featuring healthcare software producer Nextech and GV, a corporate vehicle for internet and technology group Alphabet.
The round included all the participants in the $200m series A round EQRx disclosed when it emerged from stealth in January 2020, including Andreessen Horowitz, Section 32, Casdin Capital, Arch Venture Partners and Arboretum Ventures.
The series A investors were joined by undisclosed payers and health systems, life science specialists,…
